top of page
Pink and Teal Llama Desk Strip.png

The New Standard in Scientific Due Diligence 

About Imagine Biotech

Imagine Biotech resources can call upon a wide variety of technologies to de-risk your portfolio using sophisticated pathways that have matured due to improved data resources, confounding factors, and improved model assumptions.

Our array of services ranges from sophisticated molecular modeling density functional methods (DFT) to the first-of-its-kind integration package of ADMET and PK predictions to academic risk.

Imagine Biotech staff have the training, expertise, and knowledge to review the proposed hypotheses (investment) in their entire journey to commercialization and select those tests/technologies to support further investment success or flag issues that arise only in the environment of review by skilled biotechnology experts.

Depending on which sector (antibiotics, oncology, metabolic, diagnostic), certainassets are selected as components of the report we generate for investors and, insome cases, cost less than legal reviews.

ADMET prediction with PK modeling

Investigational due diligence services

Risk intelligence reviews

CMC consulting services

Molecular docking/Pre-clinical toxicology studies

Strategic advisory consultancy 

Grant proposal support

Alan Turing Quote

"Sometimes it is the people no one can imagine anything of, who do the things no one can imagine."

- Alan Turing 

The Investor Problem

Amid economic instability and previous biotech setbacks, investors, especially Limited Partners, face declining confidence. Bottom line is that it becomes harder to close future funding rounds because of this higher historic risk profile associated to life science projects.

Traditionally, biotech investments centred on conventional business due diligence often overlook or don’t place heavy emphasis on meticulous technical analysis due to high associated cost.


Undesirable pharmacokinetics and toxicity are major reasons for drug development failures, with safety and efficacy of major concern for project success,  recognizing drug ADMET properties early reduces clinical phase failure rates.


What The Numbers Show


Average spend on pre-clinical toxicology studies


Drug discovery can take 12 years and cost $2.6 billion.


Clinical drugs fail, costing investors & partners millions


Fail because of limited pre-clinical efficacy




Fail because of unmanageable toxicity

A New Standard

It is important to keep our services in line with your desired results. The knowledge behind our reports far surpasses any one organization or database. Much like diagnostic physicians who have a substantial number of tests and imaging technologies available, the selection of which tests to find the right “answer” comes from years of training, expertise, and knowledge.

1. Exceeding Industry Standards

The predictive models used achieve an 85% accuracy rate for drug success and 91% for failure, optimizing development timelines and enhancing drug safety.

2. Employing Vast Data Banks

We have the power to filter and extract value from volumes of raw digital information housed in the world’s largest data banks. The technology we harness rapidly sift through TRILLIONS of data points, delivering comprehensive data coverage that surpasses the previous capabilities.

DALL·E 2024-04-16 21.01.29 - A full-body digital artwork depicting an x-ray view of a huma

3. Accuracy in Drug Safety and Efficacy

We are able to predict the failure of traditional drug candidates early on. This approach significantly reduces R&D costs and speeds up the delivery of effective drugs.

4. 3D structure of any API

We are able to accurately compare an Active Pharmaceutical Ingredient being developed with the 3D structure of the target protein or other molecule in the proposed mechanism of action. Where no published 3D structure exists, we will develop the most probable configuration.


JSK Therapeutics
European Institute of Bioinformatics
bottom of page